Introduction: Hereditary angioedema (HAE) with C1 esterase inhibitor deficiency (C1-INH-HAE) is a rare disease that manifests with cutaneous and/or submucosal swellings due to uncontrolled activation of the contact/kinin system. Attacks recur with unpredictable frequency and severity, laryngeal edema is potentially lethal, and the disease burden may severely disrupt patients' lives.Areas covered: This review provides an overview of lanadelumab, a human monoclonal antibody targeted against plasma kallikrein that was recently approved for prevention of symptoms in C1-INH-HAE.Expert opinion: The phase III HELP Study demonstrated the efficacy of lanadelumab in reducing HAE attacks. These positive results are being further confirmed in the open-label extension study. This agent addresses some of the limitations of existing prophylactic options as tolerability issues, the need for intravenous administration and frequent dosing. Therefore, lanadelumab can profoundly improve the quality of life of patients with C1-INH-HAE.
Keywords: C1 inhibitor deficiency; Hereditary angioedema; chronic disease; clinical efficacy; cost-effectiveness; lanadelumab; safety; tolerability.
Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.BioDrugs. 2019 Feb;33(1):33-43. doi: 10.1007/s40259-018-0325-y. BioDrugs. 2019. PMID: 30539362 Free PMC article. Review.
An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.Clin Transl Allergy. 2017 Oct 6;7:36. doi: 10.1186/s13601-017-0172-9. eCollection 2017. Clin Transl Allergy. 2017. PMID: 29043014 Free PMC article.
Lanadelumab for the treatment of hereditary angioedema.Expert Opin Biol Ther. 2019 Dec;19(12):1233-1245. doi: 10.1080/14712598.2019.1685490. Epub 2019 Nov 4. Expert Opin Biol Ther. 2019. PMID: 31657963
Lanadelumab to treat hereditary angioedema.Drugs Today (Barc). 2019 Jul;55(7):439-448. doi: 10.1358/dot.2019.55.7.2985293. Drugs Today (Barc). 2019. PMID: 31347612 Review.
Recombinant human C1 esterase inhibitor in the management of hereditary angioedema.Clin Drug Investig. 2015 Jul;35(7):407-17. doi: 10.1007/s40261-015-0300-z. Clin Drug Investig. 2015. PMID: 26091744 Free PMC article. Review.